abelheira schreef op 17 maart 2020 19:56:
Gilead Sciences - Even Not Counting COVID-19, The Company Has Significant Potential
Mar. 17, 2020 2:41 PM ET | About: Gilead Sciences, Inc. (GILD)
Gilead Sciences Filgotinib
The last aspect of Gilead Sciences’ portfolio with significant portfolio is the company’s work with Galapagos on Filgotinib. The company has been acquiring increasing stakes in Galapagos, and honestly with Gilead Sciences recent acquisitions, it might be time to buy Galapagos. It has an ~$11 billion market capitalization. Gilead Sciences already has a ~30% stake.
Filgotinib is a drug that’s rapidly achieving approval and sales growth. Filgotinib has seen its peak sales estimates grow from $2-3 billion in 2016 to $4-6 billion in 2019. That significant sales growth, which will come online with the company’s other drugs, will help to provide significant potential new income for the company. As we can see, Gilead Sciences potentially has significant growth potential in the 2020s.